Floatz logo

ERIBULIN MONOMETHANESULFONATE

Metastatic Triple-Negative Breast Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Metastatic Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Polyiclc
Washington University School of Medicine
Phase 2B
Dfn-15
Université de Sherbrooke
Phase 2B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Retifanlimab
Incyte Corporation
Phase 2B
azd6244
Gordon Mills, MD, PhD
Phase 2B

View all 39 →

Same molecule, other indications

ERIBULIN MONOMETHANESULFONATE is also rated in:

breast neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
69 / 100
View asset →
ToxicityDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →